Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.43 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.36 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.36 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.36 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.36 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.36 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.36 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.36 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.36 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.36 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.36 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.36 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL1975759 | 1.00 | KMT2A (0.43) | KMT2AMEN1LMNACYP2D6HRH1 | |
| Cadaverine Tartrate SCHEMBL5085962 | 1.00 | KMT2A (0.43) | KMT2AMEN1LMNACYP2D6HRH1 | |
| Cadaverine Tartrate SCHEMBL5623544 | 0.95 | KMT2A (0.43) | KMT2AMEN1LMNACYP2D6HRH1 | |
| Cadaverine Tartrate SCHEMBL5623548 | 0.95 | KMT2A (0.43) | KMT2AMEN1LMNACYP2D6HRH1 | |
| SCHEMBL953947 | 0.92 | KMT2A (0.50) | KMT2AMEN1LMNACYP2D6HRH1 | |
| SCHEMBL958241 | 0.92 | KMT2A (0.50) | KMT2AMEN1LMNACYP2D6HRH1 | |
| SCHEMBL4396455 | 0.92 | KMT2A (0.50) | KMT2AMEN1LMNACYP2D6HRH1 | |
| Bromide SCHEMBL4505514 | 0.90 | KMT2A (0.49) | KMT2AMEN1LMNACYP2D6HRH1 | |
| Hydrochloric Acid SCHEMBL10869034 | 0.90 | KMT2A (0.49) | KMT2AMEN1LMNACYP2D6HRH1 | |
| Bromide SCHEMBL4505510 | 0.90 | KMT2A (0.49) | KMT2AMEN1LMNACYP2D6HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2160372-A1 | METHOD FOR DETERMINING ENANTIOMERIC PURITY OF DARIFENACIN AND INTERMEDIATES | Medichem, S.A. (ES) | 2010-03-10 | — | — | EP | claimed |
| US-20090156831-A1 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | MERLI VALERIANO | 2009-06-18 | — | — | US | claimed |
| WO-2008152497-A1 | METHOD FOR DETERMINING ENANTIOMERIC PURITY OF DARIFENACIN AND INTERMEDIATES | MEDICHEM, S.A. (US) | 2008-12-18 | — | — | WO | claimed |
| US-20080312455-A1 | Method For Determining Enantiomeric Purity Of Darifenacin And Intermediates | MEDICHEM, S.A. (ES) | 2008-12-18 | — | — | US | claimed |
| US-20080269504-A1 | Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.I. | 2008-10-30 | — | — | US | claimed |
| WO-2008126106-A2 | NOVEL AND IMPROVED PROCESSES FOR THE PREPARATION OF INTERMEDIATES OF DARIFENACIN, DARIFENACIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | SATYANARAYANA REDDY MANNE (IN) | 2008-10-23 | — | — | WO | claimed |
| EP-1877393-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2008-01-16 | — | — | EP | claimed |
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-30 | — | — | US | claimed |
| US-20070197630-A1 | Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2007-08-23 | — | — | US | claimed |
| WO-2007076158-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-05 | — | — | WO | claimed |
| US-20110144354-A1 | Process for Preparation of Darifenacin and Intermediates Used in the Process | Watson Pharma Private Limited (IN) | 2011-06-16 | — | — | US | disclosed |
| WO-2010032225-A2 | PROCESS FOR PREPARATION OF DARIFENACIN AND INTERMEDIATES USED IN THE PROCESS | Watson Pharma Private Limited (IN) | 2010-03-25 | — | — | WO | disclosed |
| EP-2160372-A1 | METHOD FOR DETERMINING ENANTIOMERIC PURITY OF DARIFENACIN AND INTERMEDIATES | Medichem, S.A. (ES) | 2010-03-10 | — | — | EP | disclosed |
| WO-2009125430-A2 | IMPROVED PROCESS FOR PRODUCING DARIFENACIN | MATRIX LABORATOIRES LIMITED (IN) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009125426-A2 | NOVEL PROCESS FOR THE PREPARATION OF (3SM-[2-(2 J-DIHYDRO-5- BENZOFURANYLϊETHYL]-α.α -DIPHENYL-3-PYRROLIDINEACETAMIDE HYDROBROMIDE | NEULAND LABORATORIES LTD (IN) | 2009-10-15 | — | — | WO | disclosed |
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-30 | — | — | US | disclosed |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-23 | — | — | US | disclosed |
| US-20070197630-A1 | Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2007-08-23 | — | — | US | disclosed |
| WO-2007076158-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007076159-A2 | PURE DARIFENACIN HYDROBROMIDE SUBSTANTIALLY FREE OF OXIDIZED DARIFENACIN AND SALTS THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269504-A1 | Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof | OPRL1, OPRK1, OPRD1 | HRH1 574/4885CHRM3 87/4885ADRB2 14/4885 |
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | CHRNE, CHRM3, CHRM2 | HRH1 85/4885CHRM3 2/4885ADRB2 4/4885 |
| US-20070197630-A1 | Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof | OPRL1, OPRK1, OPRD1 | HRH1 574/4885CHRM3 87/4885ADRB2 14/4885 |
| US-20110144354-A1 | Process for Preparation of Darifenacin and Intermediates Used in the Process | OPRL1, OPRD1, OPRK1 | HRH1 334/4885CHRM3 19/4885ADRB2 10/4885 |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | HRH1 214/4885CHRM3 69/4885ADRB2 15/4885 |
| US-20080312455-A1 | Method For Determining Enantiomeric Purity Of Darifenacin And Intermediates | OPRL1, ADRB3, ADRB1 | HRH1 435/4885CHRM3 36/4885ADRB2 4/4885 |
| US-20090156831-A1 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | OPRL1, AVPR2, AVPR1B | HRH1 214/4885CHRM3 69/4885ADRB2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.